Drug Profile
Hydroxycarbamide - Cheplapharm Arzneimittel
Alternative Names: Droxia; Hydrea; Hydroxyurea; Litalir; NSC 32065; OncoCarbide; SQ 1089; WR 83799Latest Information Update: 08 Mar 2022
Price :
$50
*
At a glance
- Originator Barr Laboratories; Bristol-Myers Squibb
- Developer Barr Laboratories; Bristol-Myers Squibb; Teva Pharmaceutical Industries
- Class Antianaemics; Antineoplastics; Small molecules; Urea compounds
- Mechanism of Action Ribonucleotide reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Cancer; Sickle cell anaemia
- Discontinued HIV infections